Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) EBIAT (2019 - 2023)

Historic EBIAT for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to -$46.7 million.

  • ADC Therapeutics' EBIAT rose 767.07% to -$46.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$95.7 million, marking a year-over-year increase of 7214.28%. This contributed to the annual value of $4.7 billion for FY2022, which is 234000.66% up from last year.
  • Per ADC Therapeutics' latest filing, its EBIAT stood at -$46.7 million for Q3 2023, which was up 767.07% from -$48.9 million recorded in Q2 2023.
  • In the past 5 years, ADC Therapeutics' EBIAT ranged from a high of $43.5 million in Q1 2020 and a low of -$212.0 million during Q4 2021
  • In the last 5 years, ADC Therapeutics' EBIAT had a median value of -$59426.0 in 2023 and averaged -$31.9 million.
  • Per our database at Business Quant, ADC Therapeutics' EBIAT soared by 10002.22% in 2021 and then tumbled by 269695798.07% in 2022.
  • Quarter analysis of 5 years shows ADC Therapeutics' EBIAT stood at -$35285.0 in 2019, then tumbled by 57510.88% to -$20.3 million in 2020, then crashed by 942.94% to -$212.0 million in 2021, then surged by 99.99% to -$24157.0 in 2022, then tumbled by 193326.34% to -$46.7 million in 2023.
  • Its EBIAT stands at -$46.7 million for Q3 2023, versus -$48.9 million for Q2 2023 and -$59426.0 for Q1 2023.